MeiraGTx reports Q3 2022 net loss $37.3M; receives $25M investment from JJDC

MeiraGTx Holdings plc

2022-Q3 EPS reported -$2.29 revenue$21,208,000

Net loss of $37.3M ($0.83 per share) vs $25.9M ($0.59) in Q3 2021.
License revenue of $4.8M, down from $6.9M YoY on lower amortization from Janssen.
Cash and equivalents $114.7M at Sept 30 plus $23.7M receivables from Janssen; funded into Q4 2024.
Received $25M private placement from JJDC at $6.68/share (3.74M shares) for preclinical and manufacturing.
Dosing Phase 1 AAV-GAD for Parkinson's; XLRP Phase 3 LUMEOS on track for BLA in 2024.

item 1.01 item 2.02 item 3.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

MeiraGTx Holdings plc reported financial results for third quarter ended September 30, 2022.

Period: third quarter ended September 30, 2022
Result: reported results

Exact text from the filing

On November 10, 2022, the Company issued a press release announcing its financial results for the quarter ended September 30, 2022.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

MeiraGTx Holdings plc entered into Securities Purchase Agreement with Johnson and Johnson Innovation – JJDC, Inc. valued at approximately $25.0 million (effective 2022-11-09).

Action: entry
Agreement: equity purchase
Counterparty: Johnson and Johnson Innovation – JJDC, Inc.
Value: approximately $25.0 million
Effective: 2022-11-09

Exact text from the filing

On November 9, 2022, MeiraGTx Holdings plc (the “Company”) entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with Johnson and Johnson Innovation – JJDC, Inc.

View on SEC.gov

Browse all earnings releases →

MeiraGTx Holdings plc filing history →

Source: SEC EDGAR

accession 0001558370-22-017297

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.